4-Phenyl-2-propionylamino-thiazol | 5039-10-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-Phenyl-2-propionylamino-thiazol
• 英文别名: N-(4-phenyl-thiazol-2-yl)-propionamide；N-(4-Phenyl-thiazol-2-yl)-propionamid；N-(4-phenyl-1,3-thiazol-2-yl)propanamide
• CAS: 5039-10-1
• 化学式: C₁₂H₁₂N₂OS
• 分子量: 232.306
• InChiKey: GSSBWWLDSHUOCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯乙酮 在 吡啶 、 碘 、 丙酮 作用下， 生成 4-Phenyl-2-propionylamino-thiazol
  参考文献：
  名称：

  Ueda, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 1248,1251, 1252

  摘要：

  DOI：

文献信息

• 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS
  申请人：Kumar Sukeerthi

  公开号：US20120157411A1

  公开（公告）日：2012-06-21

  The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及2-氨基-4-芳基噻唑衍生物作为TRPA（瞬时受体电位亚家族A）调节剂。具体来说，本文描述的化合物对于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、症状和/或疾病具有用处。本文还提供了制备所述化合物的方法，用于合成它们的中间体，它们的药物组成物，以及治疗或预防由TRPA1调节的疾病、症状和/或疾病的方法。
• SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Smil David

  公开号：US20070293530A1

  公开（公告）日：2007-12-20

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof, wherein Y, L, Z, W, M, R a , R b and R c are as defined in the specification.

  这项发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，该发明提供了符合式(I)的化合物，以及它们的外消旋和内消旋混合物、非对映体和对映体： 或其N-氧化物、水合物、溶剂合物、药学上可接受的盐、前药或其复合物，其中Y、L、Z、W、M、R a 、R b 和R c 如规范中所定义。
• Heterocyclic Compounds Which Modulate The CB2 Receptor
  申请人：Bartolozzi Alessandra

  公开号：US20110312944A1

  公开（公告）日：2011-12-22

  Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  本发明揭示了调节CB2受体的化合物。根据本发明，这些化合物与CB2受体结合并作为激动剂，用于治疗炎症。那些作为激动剂的化合物还可用于治疗疼痛。
• Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor
  申请人：Hickey Eugene Richard

  公开号：US20120142666A1

  公开（公告）日：2012-06-07

  Compounds of the formula (I), (II) and (III) which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公式（I），（II）和（III）的化合物被揭示，这些化合物可以调节CB2受体。本发明的化合物结合并是CB2受体的激动剂，可用于治疗炎症。那些是激动剂的化合物还可用于治疗疼痛。
• 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS
  申请人：Glenmark Pharmaceuticals, S.A.

  公开号：US20140051667A1

  公开（公告）日：2014-02-20

  The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及2-氨基-4-芳基噻唑衍生物作为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本文所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、病况和/或疾患。本文还提供了制备所述化合物的过程、用于其合成的中间体、其制药组合物以及治疗或预防由TRPA1调节的疾病、病况和/或疾患的方法。